Vivos Therapeutics (VVOS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.11 Bn | 194.51 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 129.85 Bn | 126.37 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 119.93 Bn | 110.71 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 74.18 Bn | 73.64 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 52.54 Bn | 48.29 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.76 Bn | 32.81 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 34.25 Bn | 32.14 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.29 Bn | 22.80 Bn | 684.20 Mn | 12.92% |
| 10 | Vivos Therapeutics | 4.89 Mn | 3.09 Mn | 2.95 Mn | -9.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.81% |
| Dec 31, 2025 | -141.04% |
| Sep 30, 2025 | -106.42% |
| Jun 30, 2025 | -159.74% |
| Mar 31, 2025 | -2.68% |
| Dec 31, 2024 | -130.80% |
| Sep 30, 2024 | -24.99% |
| Jun 30, 2024 | 65.09% |
| Mar 31, 2024 | -120.96% |
| Dec 31, 2023 | 253.83% |
| Sep 30, 2023 | 61.48% |
| Jun 30, 2023 | 20.94% |
| Mar 31, 2023 | 68.05% |
| Dec 31, 2022 | 17.64% |
| Sep 30, 2022 | 0.35% |
| Jun 30, 2022 | -72.94% |
| Mar 31, 2022 | -56.84% |
| Dec 31, 2021 | 35.32% |
| Sep 30, 2021 | -164.30% |
| Jun 30, 2021 | -143.02% |